Ascendis Pharma's TransCon hGH Matches Daily Growth Hormone in Turner Syndrome Trial
Event summary
- Ascendis Pharma's Phase 2 New InsiGHTS trial showed TransCon hGH achieved comparable height velocity (9.05 cm/year) to daily somatropin in Turner syndrome patients at Week 52.
- TransCon hGH demonstrated a similar safety profile to daily somatropin with no occurrences of slipped capital femoral epiphysis (SCFE).
- The trial involved 49 children aged 1 to 10 years, randomized to either TransCon hGH or daily somatropin.
- Mean doses were 0.22 mg/kg/week for TransCon hGH and 0.29 mg/kg/week for daily somatropin.
- Ascendis is advancing a Phase 3 HighLiGHts basket trial for potential label expansion.
The big picture
Ascendis Pharma's positive Phase 2 trial results for TransCon hGH in Turner syndrome reinforce the potential of its TransCon technology platform to deliver differentiated therapies. The data supports the company's strategy of expanding indications for its lead product, addressing unmet needs in rare diseases. The biopharmaceutical industry continues to prioritize innovative drug delivery systems that improve patient compliance and outcomes, particularly in chronic conditions requiring long-term treatment.
What we're watching
- Regulatory Pathway
- Whether the Phase 3 HighLiGHts trial results will support label expansion for TransCon hGH in Turner syndrome.
- Market Differentiation
- How Ascendis positions TransCon hGH against existing daily growth hormone therapies in terms of convenience and cost.
- Commercialization Strategy
- The pace at which Ascendis can secure payer coverage and reimbursement for TransCon hGH in new indications.
Related topics